All Stories

  1. “I would never go to the doctor and speak about steroids”: Anabolic androgenic steroids, stigma and harm
  2. The Association Between the Nonmedical use of Anabolic–Androgenic Steroids and Interpersonal Violence: A Meta-Analysis
  3. Internet sourcing and unsafe use of controlled drugs (opioids, sedatives and GABA drugs) in the UK: An in depth case study of consumer dynamics during COVID-19
  4. ‘Sustaining masculinity’: a scoping review of anabolic androgenic steroid use by older males
  5. Systems mapping to understand complexity in the association between image and performance enhancing drugs (IPEDs) and harm
  6. Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise
  7. Severity of anabolic steroid dependence, executive function, and personality traits in substance use disorder patients in Norway
  8. Generating evidence on the use of Image and performance enhancing drugs in the UK: results from a scoping review and expert consultation by the Anabolic Steroid UK network
  9. Harm reduction strategies for androgen users
  10. Human enhancement drugs: Emerging issues and responses
  11. A Scoping Review of Non-Medical and Extra-Medical Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  12. Anabolic-androgenic steroid administration increases self-reported aggression in healthy males: a systematic review and meta-analysis of experimental studies
  13. Looking Beyond the Provision of Injecting Equipment to People Who Use Anabolic Androgenic Steroids: Harm Reduction and Behavior Change Goals for UK Policy
  14. “A slippery slope”: a scoping review of the self-injection of unlicensed oils and fillers as body enhancement
  15. Internet sourcing and UK end consumer trend interest in the controlled medicines (opioids, sedatives and GABA drugs) in pre and post COVID-19 timeframes
  16. How the love of muscle can break a heart: Impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health
  17. Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs
  18. 2,4 dinitrophenol: It's not just for men
  19. Monitoring the use of drugs in bodybuilding: a novel drugs early warning system
  20. Perspectives of Frontline Professionals on Palestinian Children Living with Sibling and Parental Drug Use in the UNRWA Camps, Jordan
  21. Motives and Correlates of Anabolic-Androgenic Steroid Use With Stimulant Polypharmacy
  22. Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming
  23. Anabolic-Androgenic Steroid Use in the Eastern Mediterranean Region: a Scoping Review of Extant Empirical Literature
  24. The Anabolic Androgenic Steroid Treatment Gap: A National Study of Substance Use Disorder Treatment
  25. Treatments for people who use anabolic androgenic steroids: a scoping review
  26. Engaging with people who use image and performance enhancing drugs: One size does not fit all
  27. Perspectives of Frontline Professionals on Palestinian Children Living with Sibling and Parental Drug Use in the West Bank and Gaza Strip
  28. Commentary: Steroid Madness- has the dark side of anabolic-androgenic steroids (AAS) been over-stated?
  29. The modes of administration of anabolic-androgenic steroid (AAS) users: are non-injecting people who use steroids overlooked?
  30. Palestinian Children’s Experiences of Drug Abuse in the Home in the Occupied Territories of Palestine: a Scoping Review of Extant Literature
  31. Secondary distribution of injecting equipment obtained from needle and syringe programmes by people injecting image and performance enhancing drugs: England and Wales, 2012-15
  32. An evidence-based socioecological framework to understand men’s use of anabolic androgenic steroids and inform interventions in this area
  33. Identifying a typology of men who use anabolic androgenic steroids (AAS)
  34. A systematic review investigating the behaviour change strategies in interventions to prevent misuse of anabolic steroids
  35. Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012-15
  36. Community pharmacist experiences of providing needle and syringe programmes in Ireland
  37. Adverse Effects, Health Service Engagement, and Service Satisfaction Among Anabolic Androgenic Steroid Users
  38. Anabolic steroids in the UK: an increasing issue for public health
  39. 2,4-Dinitrophenol, the inferno drug: a netnographic study of user experiences in the quest for leanness
  40. Access to needle and syringe programs by people who inject image and performance enhancing drugs
  41. A scoping review of home-produced heroin and amphetamine-type stimulant substitutes: implications for prevention, treatment, and policy
  42. Harm reduction interventions should encompass people who inject image and performance enhancing drugs
  43. Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales
  44. Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis
  45. Synthetic growth hormone releasers detected in seized drugs: new trends in the use of drugs for performance enhancement
  46. Anabolic steroids detected in bodybuilding dietary supplements - a significant risk to public health
  47. Environments, risk and health harms: a qualitative investigation into the illicit use of anabolic steroids among people using harm reduction services in the UK
  48. The composition of anabolic steroids from the illicit market is largely unknown: implications for clinical case reports
  49. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet
  50. Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking
  51. Online marketing of synthetic peptide hormones: poor manufacturing, user safety, and challenges to public health
  52. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: Systematic review of qualitative research
  53. Is the breast cancer drug tamoxifen being sold as a bodybuilding dietary supplement?
  54. Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study
  55. Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: a systematic review
  56. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study
  57. Epidemiology of Use of Novel Psychoactive Substances
  58. Drogas potenciadoras para la búsqueda de la perfección
  59. Drogas potenciadoras para la búsqueda de la perfección
  60. Social, policy, and public health perspectives on new psychoactive substances
  61. Should "legal highs" be regulated as medicinal products?
  62. Next generation challenges: An overview of harm reduction 2010, IHRA's 21st conference
  63. Adulterants in illicit drugs: a review of empirical evidence
  64. Meeting the health needs of problematic drug users through community pharmacy: A qualitative study
  65. Older and sicker: Changing mortality of drug users in treatment in the North West of England
  66. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review
  67. Injecting human growth hormone as a performance-enhancing drug—perspectives from the United Kingdom
  68. Integrating Drug-Related Monitoring Systems—An Intelligence Led Approach
  69. Elephant in the room? The methodological implications for public health research of performance-enhancing drugs derived from the illicit market
  70. Use of melanotan I and II in the general population
  71. The dire consequences of doping?
  72. Diversion and abuse of methylphenidate in light of new guidance
  73. The Involvement of Drugs and Alcohol in Drug-Facilitated Sexual Assault
  74. Problematic drug use, ageing and older people: trends in the age of drug users in northwest England
  75. The impact of citrate introduction at UK syringe exchange programmes: a retrospective cohort study in Cheshire and Merseyside, UK
  76. The role of substance use in non‐drug related deaths: a cross‐sectional study of drug treatment clients in the North West of England
  77. DRINK DETECTIVE: COMMENTS ON THE MANUFACTURER'S RESPONSE
  78. The ability of two commercially available quick test kits to detect drug-facilitated sexual assault drugs in beverages
  79. Trends in drop out, drug free discharge and rates of re-presentation: a retrospective cohort study of drug treatment clients in the North West of England
  80. Crack-cocaine injection: A retrospective analysis of clients in Merseyside specialist drug treatment agencies
  81. Effects of nightlife activity on health
  82. Effects of nightlife activity on health
  83. A potent cocktail
  84. New challenges for agency based syringe exchange schemes: analysis of 11 years of data (1991–2001) in Merseyside and Cheshire, United Kingdom
  85. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment
  86. Water usage reduction in a semiconductor fabricator